I agree with most of the previous comments and suggestions. I want only to add that this is another example of the fact that TKIs able to inhibit the ABL TK activity can be, in particular in specific patients like this one, toxic and sometimes also highly toxic. This, in my opinion, supports the concept that treatment discontinuation should really become the best goal to be achieved in CML therapy as this will probably have a long-term impact on overall survival (a part all the other advantages).